Clinical Perspectives of Theranostics

Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer an...

Full description

Bibliographic Details
Main Authors: Shozo Okamoto, Tohru Shiga, Nagara Tamaki
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Molecules
Subjects:
PET
Online Access:https://www.mdpi.com/1420-3049/26/8/2232
id doaj-5fbf646bbd3f4055bf06aab0bc9b79ca
record_format Article
spelling doaj-5fbf646bbd3f4055bf06aab0bc9b79ca2021-04-13T23:00:58ZengMDPI AGMolecules1420-30492021-04-01262232223210.3390/molecules26082232Clinical Perspectives of TheranosticsShozo Okamoto0Tohru Shiga1Nagara Tamaki2Department of Radiology, Obihiro-Kosei General Hospital, Obihiro 080-0024, JapanAdvanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima 960-1295, JapanDepartment of Radiology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, JapanTheranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. In addition, recent theranostics of radioimmunotherapy for non-Hodgkin lymphoma, and treatment of bone metastasis using bone seeking radiopharmaceuticals are described. Furthermore, new radiopharmaceuticals for prostatic cancer and pancreatic cancer have been added. Of particular, F-18 Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography (PET) is often used for treatment monitoring and estimating patient outcome. A recent clinical study highlighted the ability of alpha-radiotherapy with high linear energy transfer (LET) to overcome treatment resistance to beta--particle therapy. Theranostics will become an ever-increasing part of clinical nuclear medicine.https://www.mdpi.com/1420-3049/26/8/2232PETtheranosticsradionuclide therapycancerprognosis
collection DOAJ
language English
format Article
sources DOAJ
author Shozo Okamoto
Tohru Shiga
Nagara Tamaki
spellingShingle Shozo Okamoto
Tohru Shiga
Nagara Tamaki
Clinical Perspectives of Theranostics
Molecules
PET
theranostics
radionuclide therapy
cancer
prognosis
author_facet Shozo Okamoto
Tohru Shiga
Nagara Tamaki
author_sort Shozo Okamoto
title Clinical Perspectives of Theranostics
title_short Clinical Perspectives of Theranostics
title_full Clinical Perspectives of Theranostics
title_fullStr Clinical Perspectives of Theranostics
title_full_unstemmed Clinical Perspectives of Theranostics
title_sort clinical perspectives of theranostics
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2021-04-01
description Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. In addition, recent theranostics of radioimmunotherapy for non-Hodgkin lymphoma, and treatment of bone metastasis using bone seeking radiopharmaceuticals are described. Furthermore, new radiopharmaceuticals for prostatic cancer and pancreatic cancer have been added. Of particular, F-18 Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography (PET) is often used for treatment monitoring and estimating patient outcome. A recent clinical study highlighted the ability of alpha-radiotherapy with high linear energy transfer (LET) to overcome treatment resistance to beta--particle therapy. Theranostics will become an ever-increasing part of clinical nuclear medicine.
topic PET
theranostics
radionuclide therapy
cancer
prognosis
url https://www.mdpi.com/1420-3049/26/8/2232
work_keys_str_mv AT shozookamoto clinicalperspectivesoftheranostics
AT tohrushiga clinicalperspectivesoftheranostics
AT nagaratamaki clinicalperspectivesoftheranostics
_version_ 1721528456229945344